Business Description
Valerio Therapeutics
ISIN : FR0010095596
Total Employee Number:
25Description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 3.67 | |||||
Debt-to-EBITDA | 14.04 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 15.52 | |||||
Beneish M-Score | -4.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.5 | |||||
3-Year EPS without NRI Growth Rate | 51.9 | |||||
3-Year Book Growth Rate | -72.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.58 | |||||
9-Day RSI | 66.47 | |||||
14-Day RSI | 63.77 | |||||
3-1 Month Momentum % | 411.36 | |||||
6-1 Month Momentum % | 554.55 | |||||
12-1 Month Momentum % | 1284.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.76 | |||||
Quick Ratio | 0.76 | |||||
Cash Ratio | 0.17 | |||||
Days Sales Outstanding | 303.24 | |||||
Days Payable | 1668.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.1 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.08 | |||||
Operating Margin % | -21.38 | |||||
Net Margin % | -190.36 | |||||
EBITDA Margin % | 21.07 | |||||
FCF Margin % | 20.25 | |||||
OCF Margin % | 71.47 | |||||
ROA % | -27.41 | |||||
ROIC % | -2.39 | |||||
3-Year ROIIC % | -135.86 | |||||
ROC (Joel Greenblatt) % | -375.19 | |||||
ROCE % | -169.69 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 212.5 | |||||
PS Ratio | 121.43 | |||||
PB Ratio | 212.5 | |||||
EV-to-EBIT | -98.96 | |||||
EV-to-EBITDA | 795.36 | |||||
EV-to-Revenue | 167.54 | |||||
EV-to-Forward-Revenue | 13.69 | |||||
EV-to-FCF | 827.42 | |||||
Price-to-GF-Value | 12.01 | |||||
Price-to-Median-PS-Value | 9.34 | |||||
Earnings Yield (Greenblatt) % | -1.01 | |||||
FCF Yield % | 0.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Valerio Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.573 | ||
| EPS (TTM) (€) | -0.009 | ||
| Beta | 2.1362 | ||
| 3-Year Sharpe Ratio | 0.63 | ||
| 3-Year Sortino Ratio | 2.69 | ||
| Volatility % | 285.39 | ||
| 14-Day RSI | 63.77 | ||
| 14-Day ATR (€) | 0.052241 | ||
| 20-Day SMA (€) | 0.7404 | ||
| 12-1 Month Momentum % | 1284.62 | ||
| 52-Week Range (€) | 0.0426 - 0.93 | ||
| Shares Outstanding (Mil) | 499.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Valerio Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Valerio Therapeutics Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2024 | 2024-09-27 | 0.08 (+13.68%) |
Show
Entries
Valerio Therapeutics Frequently Asked Questions
What is Valerio Therapeutics(FRA:C4X)'s stock price today?
The current price of FRA:C4X is €0.84. The 52 week high of FRA:C4X is €0.93 and 52 week low is €0.04.
When is next earnings date of Valerio Therapeutics(FRA:C4X)?
The next earnings date of Valerio Therapeutics(FRA:C4X) is .
Does Valerio Therapeutics(FRA:C4X) pay dividends? If so, how much?
Valerio Therapeutics(FRA:C4X) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Valerio Therapeutics
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers